Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing, including time to enroll clinical studies; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, 2013 and August 19, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... years ago, Katia Silvera , a postdoctoral scholar at ... a field trip in a mountainous area in central Panama ... before. , Unable to identify it, they contacted German Carnevali, ... to be an unnamed species. So Carnevali recently named it ... the genus name, comprising about 40 species in the world. ...
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... University of Illinois have developed a new, more accurate ... that results from changes in land use. The ... Biology , takes into account many factors not included ... is an urgent need to accurately assess whether particular ...
... delivering oxygen to our vital organs are obstructed by atherosclerosis ... attack or damage to a peripheral tissue such as the ... injury or destruction from a choked-off blood supply varies from ... whose circulatory system has the best back-up plan to provide ...
... A Montreal study finds heterotrophic bacteria counts, in ... the recommended limits specified by the United States Pharmacopeia ... today at the 110th General Meeting of the American ... the cleanest tap water a large number of urban ...
Cached Biology News:Researchers calculate the greenhouse gas value of ecosystems 2Researchers calculate the greenhouse gas value of ecosystems 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 2Study pinpoints new role of molecule in the health of body's back-up blood circulation 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 4Study finds high level of bacteria in bottled water in Canada 2
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Jan. 26, 2012 Amgen (NASDAQ: AMGN ... today announced that the companies have entered into a ... a biotechnology company founded in Germany with its research ... Rockville, Md., for $11 per share in cash. The ...
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today ... shares of its common stock, including 1,950,000 shares sold pursuant ... to the underwriters. All of the shares were offered by ... share. The gross proceeds to Sequenom from this offering were ...
... Novartis Pharmaceuticals Corporation (NPC) and Sanford Wittels & Heisler, LLP, ... agreement to resolve the nationwide Wage and Hour class action ... the Southern District of New York.  NPC ... payment of up to 99 million dollars for eligible class ...
Cached Biology Technology:Amgen to Acquire Micromet 2Amgen to Acquire Micromet 3Amgen to Acquire Micromet 4Amgen to Acquire Micromet 5Amgen to Acquire Micromet 6Amgen to Acquire Micromet 7Amgen to Acquire Micromet 8Amgen to Acquire Micromet 9Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 2Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
... • Heat activated ,• ... room temperature ,• Excellent specificity allows ... and secondary structures ,• Leaves an ... chemically modified form of GeneChoice DNA Polymerase ...
... aqueous solution. Cleaves a-(1-3)- ... carbohydrates and glycoproteins. It is particularly efficient ... the pH must be neutral or above, ... Unit Definition: One unit will ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: